Prognosis Factors in Patients With Primary Central Nervous System Lymphoma

• Sponsor: Zhengzhou University (Other)
• Overall Status: Recruiting
• CT.gov ID: NCT05167630
• Collaborator: (none)
• Enrollment: 40
• Location: 1
• Anticipated Duration (Months): 99.4
• Patients Per Site Per Month: 0.4

Study Details

Study Description

Brief Summary

Primary central nervous system lymphoma (PCNSL) is a rare extranodal non-hodgkin's lymphoma confined to the central nervous system. It accounts for about 4% of all intracranial tumors and 4% to 6% of all non-Hodgkin's lymphomas . Among them, the most common type is diffuse large B cell lymphoma (DLBCL), accounting for about 95% of all cases. High dose methotrexate (HD-MTX) based chemotherapy can improve the prognosis of patients, but only 30% to 40% of patients can achieve sustained remission, and the overall prognosis is very poor[4, 6]. Currently, the International Extranodal Lymphoma Study Group (IESLG) prognostic scoring system and the Memorial Sloan Kettering Cancer Center (MSKCC) prognostic index are widely used to evaluate the prognosis in patients with PCNSL. However, IESLG model has some limitations such as the relatively small number of patients and short follow-up period. MSKCC model may have an inherent selection bias because retrospective data were collected from a single large institution. Therefore, there is a urgent need to identify novel indicators for prognosis evaluation and risk stratification in PCNSL patients.

Condition or Disease	Intervention/Treatment	Phase
PCNSL; Survival Analysis	Other: prognostic marker

Study Design

• Study Type: Observational
• Anticipated Enrollment: 40 participants
• Observational Model: Case-Only
• Time Perspective: Retrospective
• Official Title: Prognosis Factors in Patients With Primary Central Nervous System Lymphoma
• Actual Study Start Date: Sep 1, 2013
• Anticipated Primary Completion Date: Dec 15, 2021
• Anticipated Study Completion Date: Dec 15, 2021

Outcome Measures

Primary Outcome Measures

1. Overall survival [from September 1, 2013 to June 1, 2020]

   from the date of diagnosis to death from any cause or to the date of last follow-up

Eligibility Criteria

Criteria

• Ages Eligible for Study: N/A and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

(i)The pathological biopsy and immunohistochemistry diagnosis were PCNSL according to WHO diagnostic criteria for PCNSL in 2016. (ii) No treatment has been received. (iii)There were no diseases with malignant tumor, serious infection, other blood system diseases, immune system diseases and other conditions which may have great influence on peripheral blood lymphocyte count. (iv) The clinical data were complete.

Exclusion Criteria:

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Zhengzhou university	Zhengzhou	Henan	China	450052

Sponsors and Collaborators

• Zhengzhou University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Mingzhi Zhang, Dr., Zhengzhou University
• ClinicalTrials.gov Identifier: NCT05167630
• Other Study ID Numbers: hnslblzlzx20211001
• First Posted: Dec 22, 2021
• Last Update Posted: Dec 22, 2021
• Last Verified: Dec 1, 2021

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Study Results

No Results Posted as of Dec 22, 2021